Fig. 6.

METH blunts cardiac function and CSE/H₂S levels. Measurement of cardiac function and histological changes in response to METH treatment was examined between saline control, METH, METH + Sulfide, or METH + ecCSE transgenic (Tg) cohorts. Panel A reports ejection fraction %, and panel B reports fractional shortening (%), panels C shows fibrosis in heart sections by Masson's trichrome staining, which is quantified in panel D, panel E reports total sulfide levels among the various cohorts, and panel F and G, shows expressions of gp91 and p47phox respectively. N = 4–6 per cohort, #P < 0.05 vs. saline control; *P < 0.05, **P < 0.001, ***P < 0.0001 vs. METH treatment.